nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted
|
Wilz, Stephen W. |
|
|
58 |
C |
p. 49-50 |
artikel |
2 |
AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm
|
Gangemi, Sebastiano |
|
|
58 |
C |
p. 111-113 |
artikel |
3 |
Covid-19 in Brazil: A sad scenario
|
Marinho, Pedro Rafael D. |
|
|
58 |
C |
p. 51-54 |
artikel |
4 |
Cytokine storm with rapidly elevated interleukin-6 indicates sudden death in patients with critical COVID-19
|
Hu, Zhigang |
|
|
58 |
C |
p. 30-31 |
artikel |
5 |
Editorial Board
|
|
|
|
58 |
C |
p. ii |
artikel |
6 |
Glycogen synthase kinase-3: A putative target to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
|
Rana, Anil Kumar |
|
|
58 |
C |
p. 92-101 |
artikel |
7 |
Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity
|
Opdenakker, Ghislain |
|
|
58 |
C |
p. 134-140 |
artikel |
8 |
Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities?
|
Brandão, Simone Cristina Soares |
|
|
58 |
C |
p. 102-110 |
artikel |
9 |
Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy
|
Barros, Inês |
|
|
58 |
C |
p. 114-133 |
artikel |
10 |
Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19
|
Fouladseresht, Hamed |
|
|
58 |
C |
p. 32-48 |
artikel |
11 |
Response to: Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella
|
Prattichizzo, Francesco |
|
|
58 |
C |
p. 141-143 |
artikel |
12 |
SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders
|
Amruta, Narayanappa |
|
|
58 |
C |
p. 1-15 |
artikel |
13 |
SARS-CoV-2: Targeted managements and vaccine development
|
Bakhiet, Moiz |
|
|
58 |
C |
p. 16-29 |
artikel |
14 |
The cytokine storm in COVID-19: Further advances in our understanding the role of specific chemokines involved
|
Coperchini, Francesca |
|
|
58 |
C |
p. 82-91 |
artikel |
15 |
The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy
|
Li, Jing |
|
|
58 |
C |
p. 75-81 |
artikel |
16 |
Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors
|
Quarleri, Jorge |
|
|
58 |
C |
p. 55-65 |
artikel |
17 |
Type I IFN-dependent antibody response at the basis of sex dimorphism in the outcome of COVID-19
|
Gabriele, Lucia |
|
|
58 |
C |
p. 66-74 |
artikel |